

**UNITED STATES DEPARTMENT OF COMMERCE****United States Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

HA

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/384,379 08/27/99 AOKI

Y 2167-0110P

002292 HM22/0913
BIRCH STEWART KOLASCH & BIRCH
PO BOX 747
FALLS CHURCH VA 22040-0747

EXAMINER

NGUYEN, R

ART UNIT

PAPER NUMBER

1641

DATE MAILED:

09/13/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No.

09/384,379

Applicant(s)

Aoki et al

Examiner

Bao-Thuy L. Nguyen

Art Unit

1641

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 29 June 2001.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-5 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-5 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ 6) ☐ Other: _____

Art Unit: 1641

DETAILED ACTION

1. Applicant's request for reconsideration filed June 29, 2001 has been received.
2. The rejection of claims 1-5 under 35 USC 102(a) as being clearly anticipated by Japanese Patent No. JP-11151085 A is withdrawn in light of the request.
3. Claims 1-5 are pending.

Claim Rejections - 35 USC § 103

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

5. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).
6. Claims 1-5 are rejected under 35 U.S.C. 103(a) as being unpatentable over Aoki et al (Clinica Chimica Acta, 178:193-204, 1988) in view of Kohler (Science, 233:1281-1286, 1986).

Aoki et al disclosed an enzyme immunoassay method for the determination of human medullasin in a peripheral blood. Aoki et al disclosed beads coated with IgG obtained from immunized rabbits ~~were~~ incubated with medullasin, Fab'-peroxidase conjugate was added, and peroxidase activity bound to the beads was measured by a fluorophotometer. Aoki et al disclosed that the determination of

Art Unit: 1641

medullasin activity in granulocytes of patients with multiple sclerosis is useful in both diagnosis and evaluation of the disease. See pages 194-196.

Aoki et al differ from the instant invention in failing to teach a monoclonal antibody to medullasin.

Kohler, however, disclosed a method for producing hybridoma cell lines secreting monoclonal antibodies using lymphocyte fusion techniques. Kohler disclosed that polyclonal antibodies suffers from major disadvantages such as low titers, the polyclonal antibodies are heterogeneous, limited supply and that it is impossible to reproduce the same combination of specific antibodies in a new animal. In contrast, lymphocyte fusion provides the advantages of specificity, unlimited supply of antibody. The use of impure antigens still leads to pure antibody reagents. All specificities can be rescued. Enrichment or specific hybridomas is possible. A high level of antibody secretion is observed. The hybridoma cell lines can be manipulated to produce^e antibodies not found in nature, and the method is general such that antibodies against any antigen may be produced. See page 1281.

Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to produce a monoclonal antibody against the human medullasin of Aoki et al using the method of Kohler because Kohler teaches that any substance that can elicit a humoral response can be used to prepare monoclonal antibodies, and that monoclonal antibodies provides advantages not found in polyclonal antibodies. These advantages include specificity of binding, homogeneity, and ability to be produced in unlimited quantities. The product of monoclonal antibodies allows the isolation of reagents with a unique, chosen specificity. Because all of the antibodies produced by descendants of one hybridoma cell are identical, monoclonal antibodies are powerful reagents for testing for the presence of a desired epitope. In addition, one unique advantage of hybridoma production is that impure antigens can be used to produce specific antibodies. A skilled artisan would have had a reasonable expectation of success and would have been motivated to use the techniques of Kohler to produce monoclonal

Art Unit: 1641

antibodies to the human medullasin of Aoki et al because such techniques are well known in the art and provides advantages not found with polyclonal antibodies.


Conclusion

7. No claim is allowed.

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bao-Thuy L. Nguyen whose telephone number is (703) 308-4243. The examiner can normally be reached on Monday, Wednesday and Thursday from 9:00 - 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long V. Le can be reached on (703) 305-3399. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 308-3014 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.



Bao-Thuy L. Nguyen
Primary Examiner
Art Unit 1641
September 10, 2001